{"id":132670,"date":"2026-05-20T07:00:20","date_gmt":"2026-05-20T11:00:20","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670"},"modified":"2026-05-20T07:00:20","modified_gmt":"2026-05-20T11:00:20","slug":"new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670","title":{"rendered":"New drug approach offers hope for patients with recurrent aggressive cancers"},"content":{"rendered":"
\n

A new treatment for endometrial cancer<\/a> demonstrated strong potential in a Phase 3 clinical trial.<\/p>\n

Drugmaker Merck announced Monday that the investigational drug sacituzumab tirumotecan (sac-TMT) met its “primary endpoints” of overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer<\/a>.<\/p>\n

The TroFuse-005 trial is the first global Phase 3 trial to “demonstrate statistically significant improvement” in survival compared to chemotherapy in these patients, according to a Merck press release.<\/p>\n

WEIGHT-LOSS DRUGS NOW LINKED TO CANCER PROTECTION IN WOMEN, MAJOR NEW STUDY REVEALS<\/strong><\/a><\/p>\n

This was also the first and only antibody-drug conjugate (ADC) to achieve such a result for endometrial cancer patients in this setting, the researchers stated.<\/p>\n

An ADC is a targeted cancer therapy that delivers more of the drug to tumor cells while limiting damage to healthy cells.<\/p>\n

The trial involved 776 patients with endometrial cancer whose disease worsened after receiving both platinum chemotherapy and immunotherapy<\/a>.<\/p>\n

The patients were randomly assigned sac-TMT, administered every two weeks, or a treatment of the physician\u2019s choice, including doxorubin or paclitaxel chemotherapy. The patients were aware of which treatment they were receiving.<\/p>\n

Those receiving sac-TMT showed “clinically meaningful improvement” in their disease state compared to the treatment of physician\u2019s choice<\/a>, the researchers found.<\/p>\n

The study also met response rate benchmarks and exhibited similar side effects to earlier studies of the same drug, Merck reported.<\/p>\n

NEW BREAST CANCER DRUG WINS FDA APPROVAL AFTER SLASHING PROGRESSION RISK BY NEARLY 40%<\/strong><\/a><\/p>\n

The drugmaker did not disclose any statistics on exact survival benefit, response rate, side effect rates or other details, but the researchers aim to present this Phase 3 data at an upcoming medical meeting.<\/p>\n

Dr. Domenica Lorusso, the study\u2019s global lead investigator and professor of obstetrics and gynecology at Humanitas University and Humanitas San Pio X in Milan, wrote in a press release that these results show sac-TMT “may be able to address a critical unmet need for certain patients with advanced endometrial cancer, one of the only cancers increasing in both incidence and mortality worldwide.”<\/p>\n

CLICK HERE FOR MORE HEALTH STORIES<\/strong><\/a><\/p>\n

“Despite recent advances, patients whose disease progresses following treatment with platinum and immunotherapy are urgently in need of new options, and these findings show for the first time that a TROP2 ADC may be an effective option in this setting,” she added.<\/p>\n

Dr. Brian Slomovitz, co-director of gynecologic oncology at Mount Sinai and an investigator on this trial, reflected on the study findings during an interview with Fox News Digital.<\/p>\n

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER<\/strong><\/a><\/p>\n

“Unlike many other cancers that we are treating, the number of endometrial cancers and the number of deaths due to endometrial cancers are on the rise,” Slomovitz noted.<\/p>\n

“In the United States, the number of deaths due to endometrial cancer has surpassed the\u00a0number of deaths due to ovarian cancer<\/a>, [making it] the deadliest of all gynecologic malignancies.”<\/p>\n

Despite recent advancements introducing immunotherapy as the standard of care, “better treatment options” for patients with recurrent disease “remains an unmet need,” Slomovitz commented.<\/p>\n

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ<\/strong><\/a><\/p>\n

“If the full data confirm this announcement, the key questions will be the magnitude of the survival benefit and the toxicity profile \u2014 those will define sac-TMT\u2019s role,” he said.\u00a0<\/p>\n

“But an overall survival improvement<\/a> in recurrent disease is a real, meaningful result for patients and their families, not just a statistical one.”<\/p>\n<\/div>\n

Source – https:\/\/www.foxnews.com\/health\/new-drug-approach-offers-hope-patients-recurrent-aggressive-cancers <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

A new treatment for endometrial cancer demonstrated strong potential in a Phase 3 clinical trial. Drugmaker Merck announced Monday that the investigational drug sacituzumab tirumotecan […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[16563],"tags":[],"stock_ticker":[],"class_list":["post-132670","post","type-post","status-publish","format-standard","hentry","category-market-news","entry"],"acf":[],"yoast_head":"\nNew drug approach offers hope for patients with recurrent aggressive cancers - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New drug approach offers hope for patients with recurrent aggressive cancers - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"A new treatment for endometrial cancer demonstrated strong potential in a Phase 3 clinical trial. Drugmaker Merck announced Monday that the investigational drug sacituzumab tirumotecan […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-20T11:00:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2021\/06\/businessman-showing-business-evolution1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"715\" \/>\n\t<meta property=\"og:image:height\" content=\"423\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/6e00efa2abc413bdc0bca51a90c54d36\"},\"headline\":\"New drug approach offers hope for patients with recurrent aggressive cancers\",\"datePublished\":\"2026-05-20T11:00:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670\"},\"wordCount\":579,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"articleSection\":[\"Market News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670\",\"name\":\"New drug approach offers hope for patients with recurrent aggressive cancers - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"datePublished\":\"2026-05-20T11:00:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New drug approach offers hope for patients with recurrent aggressive cancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/6e00efa2abc413bdc0bca51a90c54d36\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/09\/360_F_336393115_5gCUfwn76x3MJaCJMYDKLoRebkC8QyrL-300x300.jpg\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/09\/360_F_336393115_5gCUfwn76x3MJaCJMYDKLoRebkC8QyrL-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/09\/360_F_336393115_5gCUfwn76x3MJaCJMYDKLoRebkC8QyrL-300x300.jpg\",\"caption\":\"admin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/admin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New drug approach offers hope for patients with recurrent aggressive cancers - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670","og_locale":"en_US","og_type":"article","og_title":"New drug approach offers hope for patients with recurrent aggressive cancers - Wall Street PR","og_description":"A new treatment for endometrial cancer demonstrated strong potential in a Phase 3 clinical trial. Drugmaker Merck announced Monday that the investigational drug sacituzumab tirumotecan […]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2026-05-20T11:00:20+00:00","og_image":[{"width":715,"height":423,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2021\/06\/businessman-showing-business-evolution1.jpg","type":"image\/jpeg"}],"author":"admin","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670"},"author":{"name":"admin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/6e00efa2abc413bdc0bca51a90c54d36"},"headline":"New drug approach offers hope for patients with recurrent aggressive cancers","datePublished":"2026-05-20T11:00:20+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670"},"wordCount":579,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"articleSection":["Market News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670","url":"https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670","name":"New drug approach offers hope for patients with recurrent aggressive cancers - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"datePublished":"2026-05-20T11:00:20+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/new-drug-approach-offers-hope-for-patients-with-recurrent-aggressive-cancers-132670#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"New drug approach offers hope for patients with recurrent aggressive cancers"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/6e00efa2abc413bdc0bca51a90c54d36","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/09\/360_F_336393115_5gCUfwn76x3MJaCJMYDKLoRebkC8QyrL-300x300.jpg","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/09\/360_F_336393115_5gCUfwn76x3MJaCJMYDKLoRebkC8QyrL-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2022\/09\/360_F_336393115_5gCUfwn76x3MJaCJMYDKLoRebkC8QyrL-300x300.jpg","caption":"admin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/admin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/132670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=132670"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/132670\/revisions"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=132670"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=132670"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=132670"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=132670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}